Amneal insider acquires 12.8M shares via Kashiv deal

Amneal Pharmaceuticals, Inc. reported that reporting person Tushar Bhikhubhai Patel, a greater-than-10% owner, indirectly acquired 12,763,469 shares of Amneal Class A common stock.

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. reported that reporting person Tushar Bhikhubhai Patel, a greater-than-10% owner, indirectly acquired 12,763,469 shares of Amneal Class A common stock. The shares are held through limited liability companies controlled by family trusts.

The acquisition occurred on August 10, 2026 as part of Amneal’s purchase of 100% of Kashiv BioSciences, LLC membership interests. Deal consideration included $375,000,000 in cash (subject to purchase price adjustments) and 28,942,098 Amneal Class A shares. Following this transaction, entities associated with Patel held 61,341,678 Class A shares indirectly.

Insider Trade Summary

Grant/Award: 12,763,469 shares

Grant/Award 1 txn

Insider Patel Tushar Bhikhubhai

Role 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock F1	12,763,469	--	--

Holdings After Transaction: Class A Common Stock — 61,341,678 shares (Indirect, By Limited Liability Companies Controlled by Family Trusts)

Footnotes (1)

1. F1. On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC and the equityholders of Kashiv named therein (the "Sellers"), a subsidiary of the Issuer purchased (the "Acquisition") from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock ("Class A Common Stock"). Pursuant to the terms of the Purchase Agreement, a limited liability company managed by the Reporting Person received 12,763,469 shares of Class A Common Stock in the Acquisition.

Key Figures

Shares acquired: 12,763,469 shares Post-transaction holdings: 61,341,678 shares Cash consideration for Kashiv: $375,000,000 +1 more

4 metrics

Shares acquired 12,763,469 shares Class A common stock indirectly acquired on August 10, 2026

Post-transaction holdings 61,341,678 shares Indirect Class A holdings by entities associated with reporting person after transaction

Cash consideration for Kashiv $375,000,000 Cash portion of aggregate consideration to acquire 100% of Kashiv BioSciences, LLC

Stock consideration for Kashiv 28,942,098 shares Amneal Class A shares issued as part of Kashiv BioSciences acquisition consideration

Key Terms

Membership Interest Purchase Agreement, purchase price adjustments, Class A common stock, indirect ownership

4 terms

Membership Interest Purchase Agreement regulatory

"pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026"

A membership interest purchase agreement is a contract used when someone buys an ownership stake in a limited liability company (LLC). It spells out what is being sold, the price, any promises about the business’s condition, and who takes responsibility for debts or legal issues—like a receipt and rulebook for the sale. Investors care because it transfers control, affects future cash flow and liabilities, and can change the value and tax treatment of their investment.

purchase price adjustments financial

"for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments"

Purchase price adjustments are changes made to the agreed sale price of a company after closing to reflect actual financial facts—like cash on hand, debts, or inventory—found when final accounts are prepared. Think of it as the final bill after a home inspection: the buyer and seller settle differences so the price matches reality. For investors, these adjustments affect the true cost, future earnings and cash flow from a deal, and therefore the value of the investment.

Class A common stock financial

"28,942,098 shares of Issuer Class A common stock ("Class A Common Stock")"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

indirect ownership financial

"ownership type is indirect, by limited liability companies controlled by family trusts"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Tushar Bhikhubhai Patel report in Amneal (AMRX) on August 10, 2026?

Tushar Bhikhubhai Patel reported indirectly acquiring 12,763,469 shares of Amneal Class A common stock on August 10, 2026, held through limited liability companies controlled by family trusts and tied to the Kashiv BioSciences acquisition.

How many Amneal (AMRX) shares does Tushar Bhikhubhai Patel hold after this Form 4 transaction?

After the reported transaction, entities associated with Tushar Bhikhubhai Patel held 61,341,678 shares of Amneal Class A common stock indirectly, through limited liability companies controlled by family trusts, as disclosed in the Form 4 filing.

What were the total consideration terms for Amneal (AMRX) acquiring Kashiv BioSciences, LLC?

Amneal’s subsidiary agreed to acquire 100% of Kashiv BioSciences, LLC membership interests for $375,000,000 in cash, subject to purchase price adjustments, plus 28,942,098 shares of Amneal Class A common stock as stock consideration.

How many Amneal (AMRX) shares did entities managed by Tushar Patel receive in the Kashiv acquisition?

Under the Purchase Agreement for Kashiv BioSciences, a limited liability company managed by Tushar Bhikhubhai Patel received 12,763,469 shares of Amneal Class A common stock as part of the stock consideration issued in the acquisition.

Is the reported Amneal (AMRX) Form 4 transaction a market purchase or sale?

The reported Form 4 shows a grant, award, or other acquisition of 12,763,469 shares tied to Amneal’s acquisition of Kashiv BioSciences, rather than an open-market purchase or sale, and is categorized as an indirect ownership transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 06:07 PM Accepted by SEC EDGAR 08/12/2026 - 06:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Tushar Bhikhubhai

(Last) (First) (Middle)

C/O TARSADIA INVESTMENTS

520 NEWPORT CENTER DRIVE, 21ST FLOOR

(Street)

NEWPORT BEACH CALIFORNIA 92660

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/10/2026		A(1)		12,763,469	A	(1)	61,341,678	I	By Limited Liability Companies Controlled by Family Trusts

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC and the equityholders of Kashiv named therein (the "Sellers"), a subsidiary of the Issuer purchased (the "Acquisition") from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock ("Class A Common Stock"). Pursuant to the terms of the Purchase Agreement, a limited liability company managed by the Reporting Person received 12,763,469 shares of Class A Common Stock in the Acquisition.

	Tushar Patel	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)